Key Highlights
- Beth Shafer, Ph.D. joins Scholar Rock as Chief Business Officer.
- Over 20 years of biopharma leadership and corporate strategy expertise.
- Will guide long-term business development strategy at Scholar Rock.
- Appointment comes at a transformative time for the company.
- Scholar Rock’s innovative pipeline includes cardiometabolic disorders and SMA treatments.
Source: Business Wire
Notable Quotes
- “Beth brings broad corporate strategy and business development experience which will be critical as we build an integrated biopharmaceutical company for the future.” — Jay Backstrom, M.D., MPH, President and CEO at Scholar Rock
- “I look forward to working with the team to maximize the reach of Scholar Rock’s potentially transformative therapies.” — Beth Shafer, Ph.D., Chief Business Officer at Scholar Rock
SoHC's Take
The appointment of Beth Shafer, Ph.D., as Chief Business Officer is a strategic move for Scholar Rock as it continues to advance its innovative treatments in high-value therapeutic areas such as spinal muscular atrophy and cardiometabolic disorders. With Shafer’s extensive leadership background, particularly in business development across key pharmaceutical sectors, Scholar Rock is poised to strengthen its corporate strategy and drive the development of groundbreaking therapies that target unmet medical needs. Her experience from global companies like Takeda, Novartis, and Roche will be invaluable as Scholar Rock seeks to scale its operations and bring transformative therapies to market.
